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Abstract: Glycosylation is a promising approach to overcome antimicrobial drug resistance. In this 
study, we investigated Koenigs-Knorr and phase transfer glycosylation on novobiocin. While the 
former only gave a 4'-OH product, the later produced mainly a kinetic controlled 5-OH product, but 
still achieved the 4'-OH modification and novoise-glycosylated products (with stronger base), as well 
as a diglycosylated compound. Investigation on the antibacterial activity indicate that the presence of 
galactose moiety helps to improve activity possibly via enhanced cellular uptake. 
1. Introduction 
Antimicrobial agents are the last line of defence against microorganisms. Overuse and/or misuse of 
antibiotics has been linked to resistant organisms such as multidrug resistant (MDR) Gram-negative 
bacteria, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci 
(VRE). Such organisms are responsible for 25,000 deaths each year and more than €1.5 billion in 
healthcare-associated expenses and productivity losses in Europe alone.[1] Consequently, efforts have 
now hastened to find new strategies to address the increasing resistance problem; one promising 
approach is to modify a compound by glycosylation.[2] Many antibiotics are glycosylated and contain 
a variety of different sugars.[3-7] Glycosylation modifies antimicrobial agent pharmacokinetic 
parameters such as solubility, membrane transport, pharmacodynamics, mechanism and potency.[8] 
The sugar residues can increase or decrease potency[9, 10] either by being directly involved in the 
binding process [11, 12] or by being essential for antimicrobial activity [13]. 
Novobiocin is a member of the aminocoumarin family and acts as a bacterial DNA synthesis inhibitor 
by binding to the B subunit of the DNA gyrase.[14] It also possess anticancer activity by binding to the 
HSP90 chaperone.[15, 16] The clinical use of this class of antibiotics has been restricted due to their 
low water solubility, low activity against Gram-negative bacteria [17] and toxicity in vivo.[18] 
Modifications of aminocoumarins have been made to achieve better activity in the past decade.[19-
22] Previously we discovered that novobiocin can be glycosylated by glycosyltransferases. This simple 
glycosylation separates the anticancer activity from antibacterial activity up to 2.67×104 fold.[23] 
However, the exact mechanism is not fully clear. 
2. Result and discussion  
2.1 Phase transfer glycosylation 
Previously, the glycosylated novobiocins were obtained either via enzymatic catalyzed synthesis, 
which was difficult to scale up or involves the use of mercury cyanide which is extremely toxic. In order 
to find an alternative synthetic route, we tested a few conditions, such as Koenigs-Knorr (Fig. 1, Table 
1) and phase transfer glycosylation  ( Fig. 2, Table 2) with different solvents, catalysts and temperature. 
In the Koenigs-Knorr reactions, only DMF, a polar aprotic solvent, gave reasonable yield (31%) with 
the tetra-acetylated glucosyl bromide donor and novobiocin due to its strong solvent effect and 
capacity to fully solubilise novobiocin. Adding catalyst or increase temperature led to a decrease the 
yield (Table 1) probably because the reaction was slow and a fast forming oxinium intermediate was 
not in favour of the desired product. However, it should be noted that under these conditions, only 
glycosylation on the 4'-OH was formed (Fig. 1, Fig. S1). 
 
Figure 1. Glycosylation with Koenigs-Knorr condition. 
Table 1.Glycosylation of novobiocin with various conditions. 
No Solvent Catalyst Eqv. Temp/C RT /min Mass (ESI +) Yield 
1 THF Hg(CN)2 1.2 rt 3.78 943 57% 
2 THF AgBF4 1.1 rt - - - 
3 THF AgOTf 1.1 rt 3.82 - Trace 
4 THF CuOTf 1.1 rt - - - 
5 DMF no 1.1 rt 3.82 943 31% 
6 DMF no 1.1 45 3.81 943 14% 
7 DMF AgCO3 1.1 rt 3.82 943 17% 
8 DMF BiONO3 1.2 rt 3.81 943 11% 
9 DMF AgOTf 1.1 rt 3.81 943 10% 
10 DMF K2CO3 1.1 rt 3.80 943 9% 
11 DMF LiBr 1.1 rt - 
  
12 PC no 1.1 rt 3.79 943 15% 
Eqv: Equivalent. rt: room temperature. RT: retention time. Yield: estimated from LC UV spectra. PC: 
Propylene carbonate.  
 
Phase transfer reaction conditions (Fig. 2, Table 2) suggested that chloroform was a better solvent 
than DCM and that a higher equivalent of benezyl tributyl ammonium bromide (BTAB) and stronger 
(CO32-vs HCO3-) base favoured a better yield. However, it should be stressed that it produced a 
different glycosylation product with different retention time (4.6 min instead of 3.8 min, Table 2, Fig. 
S2). Ion trap analysis; while all major MS3 peaks could be confidently assigned, the ion of 518.08 
proved a 5-OH glycosylation (Fig. 2). The structure was further validated by NMR (Table S1) - a coupling 
between H1''' and C5 indicated the linkage. At elevated temperature (Table 2, No 19) the 4'-OH (3.8 
min) and 5-OH glycosylated products could be observed as well as a diglycosylated product (Fig. S3). 
As the 5-OH is more accessible but with higher pKa values [23] compared to 4'-OH, this probably 
means that the increase in temperature changed the reaction from kinetic  to thermodynamic control. 
The much stronger base (OH-) caused decarbamation of novobiocin and its glycosylated product, but 
produced another glycosylated product (4.98 min) which may possibly occur on the 2''-OH in noviose 









 Figure 2. Glycosylation with phase transfer condition and MS/MS analysis of products. Top: reaction 
scheme; bottom: MS/MS analysis of compound 6 to elucidate the structure. MS1: full MS spectrum. 
941.34, [M-H+]-. MS2: MS/MS analysis of 941. Peaks of 898.36 and 724.32 are indicated in the reaction 
scheme (red cleavage). MS3: MS3 analysis of 724.32 in MS2. The peak of 518.08 indicated that glucose 
moiety was added onto the phenol-OH (5-OH). Peaks of 682.32 and 664.22 are indicated in the scheme 
(Top, green cleavage). Peak of 621.97 was formed from peak 664.22 by removing one of the acetyl 
groups 
Table 2. Phase transfer condition for the synthesis of glucosyl-novobiocin.  
Entry Promoter Eqv. Water/Organic Donor 
/Eqv. 
Temp/C RT/min Mass 
(ESI+) 
Yield 
13 BTAB 0.1 Water/DCM 1.1 rt -     
14 BTAB 0.1 0.1M NaHCO3/DCM 1.1 rt -     
15 BTAB 0.1 0.15M K2CO3/ DCM 1.1 rt 4.59 943 12% 
16 BTAB 1 0.15M K2CO3/DCM 1.1 rt 4.60 943 16% 
17 BTAB 1 0.15M K2CO3/DCM 4 rt 4.59 943 30% 
18 BTAB 1 0.15M K2CO3/CHCl3 4 rt 4.60 943 45% 
19 BTAB 1 0.15M K2CO3/CHCl3 4 45 3.76 943 28% 
            4.10 1273 29% 
            4.55 943 9% 
20 BTAB 1 0.08 M KOH/CHCl3 4 rt 4.42 570 25% 
      4.68 900 25% 
      4.98 943 18% 
Note: BTAB: Benzyltributylammonium Bromide. rt, room temperature. RT: retention time. 4-
glycosylated product marked in red.  Phenol-glycosylated product marked in blue. There is also an 
unidentified product marked in green which could be another glycoside of novobiocin due to its 
identical molecular weight. Yield: estimated from LC UV spectra. 
In No 19, product RT=4.10 min is characterized as double-glycosylated product of novobiocin.  
In No 20, product RT=4.42 min is characterized as novobiocin lost its carbamate group located on 
novoise sugar. As a result, product RT=4.68 min is the glycoside of product RT=4.42 min. 
 
Figure 3 shows the HMBC-NMR of compounds 4 & 5, obtained in the presence of DMF alone. Both 
H1''' from a sugar coupled with C4' in the coumarin ring clearly proved the glycosylation on the 4'-OH 
position. While most other peaks retain the same chemical shifts both in HNMR and CNMR, the sugar 
moiety (red for glucose and blue for galactose) showed quite different shift and coupling constants, 
especially H4'''. Most three bonds long range couplings could be observed such as within the 2 ppm 
and 65 ppm regions, and a proton from an acetyl group coupled to 2''' to 6''' respectively, but not 5'''. 
Compounds 2 & 3 were obtained by deprotection of 4 &5 respectively according to procedures 
reported previously. [23] 
 *  
Figure 3. Combined HMBC NMR analysis of tetra-O-acetyl-β-glucosyl-novobiocin (Red) and 
galactosylnovobiocin (Blue). Both spectra indicated the binding between H1''' to 4' (Green). Long 
range couplings can be observed on acetyl CH3 to 2''' to 6''' but not 5'''. Unlabelled peaks are 1H 
coupled 13CNMR peak. *: solvent residues. 
2.2 Biological activity test 
Novobiocin inhibits DNA supercoiling catalyzed by DNA gyrase. DNA gyrase activity assays were carried 
out on 1, 2 and 3 (Fig. 4). 1 showed inhibition at 0.5 M, which is consistent with the value reported 
in the literature (0.9 µM[24]). 2 and 3 inhibited DNA gyrase at 5 and 10 µM, respectively. This indicates 
that adding a sugar residue on novobiocin reduced the DNA gyrase-binding capacity of the compound. 
The crystal structure of the DNA gyrase (PDB id:1AJ6) was used as a receptor in docking studies using 
ICM-Pro Molsoft software.[25] Compound 1 was re-docked to the same position within the crystal 
structure, the binding energy of1 (-25.84 kcal/mol), 2 (-21.32 kcal/mol) and 3 (-19.35 kcal/mol) are in 
agreementwith the gyrase assay result. Compounds 2 and 3 are in the same position as compound 1, 
with noviose moieties in the pocket. In all three cases, we observed hydrogen bond between ligands 
(noviose moieties) and residues N46, T165 and D73, which contribute to the binding pocket. The 
added sugar in 2 and 3 creates new hydrogen bonds with residue R76 (Fig. 4). 
The in vitro antibacterial activities of 1- 5 were evaluated against several clinically relevant bacteria 
(Table S2). Neither novobiocin or modified novobiocin derivatives showed strong antibacterial activity 
against various strains. Galactosyl-novobiocin (3) showed about 2-fold increased potency probably 




Figure 4. Antibiotics effect of compounds 1-3. a) Effect on the capacity of DNA gyrase to supercoiled 
relaxed pBR322 DNA.-, relaxed pBR322 without DNA gyrase; OC, open circular plasmid DNA; C, coiled 
plasmid DNA; SC, supercoiled, unit: M. Top: Novobiocin (1); Middle: glucosyl_novobiocin (2) and 
Bottom; galactosyl_novobiocin (3).[23] b) DNA gyrase protein structure (PDB ID: 1AJ6) with re-docked 
1 (violet), and docked compound 2 (pink) and 3 (blue). Both2 &3 interact with the pocket in the same 
way like 1 by creating four hydrogen bonds between the noviose moiety and residues N46,  T165 and 
D73. The glucose/galactose moieties create new hydrogen bonds with residue R76. Yellow lines: 
hydrogen bonds. c) A zoomed-out image of glucose/galactose binding positions from b). 
3. Experimental  
3.1 General method of Koenigs-Knorr glycosylation (Table1, 1-4) 
A mixture of novobiocin sodium (2.0g, 3.159mmol), 1-Bromine-2,3,4,6-tetra-O-acetyl-α-D-
glucose/galactose (1.32g, 3.218 mmol), activated4Å molecular sieves (approx. 6 g) and anhydrous THF 
(100mL) were added into a 250ml flask. Catalyst (1.0eqv) was added into the system and then the 
reaction mixture was stirred for 7 days under nitrogen at room temperature covered by foil and 
monitored by LC/MS (Shimazu 2020, Column: XTerra, C-18, 2.5um,4.6mm, solvent A 0.1 FA in water, 
solvent B 0.1%FA in ACN, t = 0, 10% B, t = 4 min, 95% B, t = 5.2 min, 10% B, t = 7 min, 10% B. The 
reaction mixture was filtered and washed with potassium iodide (2M, 25mL×2 if used Hg(CN)2), 
saturated NaHCO3 (10 mL×2) and dried with sodium sulphate.The solvent was removed by vacuum to 
afford a light brown crude product. Then the crude product was purified by flash column (ethyl 
acetate/petroleum ether/methanol 12/4/1,) to afford a white powder (yield; see Table 1) 
3.2 Generalmethod of glycosylation using DMF as solvent (Table 1, 5-12) 
A mixture of novobiocin sodium (200 mg, 0.32 mmol), 1-Bromine-2,3,4,6-tetra-O-acetyl-α-D-
glucose/galactose (0.132g, 0.32mmol), activated 4Å molecular sieves (approx. 1.5g) and anhydrous 
DMF (anhydrous, 20ml, or other solvent as in Table 1) were added into a 250 ml flask. Catalyst (eqv. 
shown in Table 1) was added into the reaction. The reaction mixture was stirred for 3 days under 
nitrogen gas protection at room temperature covered by foil and monitored by LC/MS. Water (120ml) 
was added into the system and the crude product was extracted by chloroform. The crude product 
was purified by flash column (ethyl acetate/petroleum ether/methanol 12/4/1, Rf = 0.3) to afford a 
white powder (yield; see Table 1). 
3.3 General method of phase transfer glycosylation of novobiocin 
Novobiocin (20mg 0.03mmol) was weighed and dissolved in a beaker that already contained 5 ml 0.15 
M potassium carbonate water solution, stirred for 15 minutes.  α-1-Bromine-2,3,4,6-tetra-O-acetyl-D-
glucose (53.9mg, 0.12mmol)  and benzyltributylammonium bromide (11.4mg, 0.03mmol) were 
dissolved in 5ml chloroform. When the stirring of water-phase was complete, the colourless solution 
inside the beaker was transferred into the flask and little amount of 0.15M potassium carbonate water 
solution was used to wash the beaker. Once the separation of two layers was finished, the whole 
system was put into a 45Coil bath (or room temperature) and stirred overnight. Organic layer was 
monitored by LC/MS. The water phase inside was removed and the organic phase was washed with 
saturated NaHCO3 (20mL), brine (10mL) and deionized water (10mL× 2). The brown organic phase was 
then concentrated under vacuum to obtain an orange solid residue and purified by Biotage reverse 
phase column (yield see Table2). Compound 6 was separated using prep-HPLC under linear gradient 
condition within 200 min. 1HNMR (400 MHz, MeOD4): δ = 7.66 (1 H, s, H3), 6.01 (1 H, d, J = 8.8 Hz, H6),  
7.67 (1 H, d, J = 8.9 Hz, H7), 3.12 (2 H, m, H8), 5.10 (1 H, m, H9), 1.54 (6H, s, H11, H12), 7.63 (1 H, d, J 
= 8.8 Hz, H5'), 7.00 (1 H, d, J = 8.7 Hz, H6'), 2.11 (3 H, s, H11'), 5.36 (1 H, d, J = 1.88 Hz, H1''), 4.04 (1 H, 
m, H2''), 5.15 (1 H, dd, J = 3.18, 9.93 Hz, H3''), 3.40 (1 H, d, J = 12.6 Hz, H4''), 1.16 (3 H, s, H6''), 0.98 (3 
H, s, H7''), 3.37 (3 H, s, H8''); 5.20 (1 H, d, J = 7.9 Hz, H1'''), 5.26 (1 H, m, H2''''), 5.30 (1 H, m,H3''''), 5.12 
(1 H, m, H4''''), 4.18 (1 H, m, H5''''), 4.03 (2 H, m, 2 * H6''''), 1.80-2.01 (12 H, s, 4*CH3CO).13CNMR (125 
MHz, MeOD4): δ = 169.35 (C1), 158.35 (C2), 130.77 (C3), 125.03 (C4), 159.15 (C5), 110.41 (C6), 128.23 
(C7), 29.16 (C8), 123.21 (C9), 134.0 (C10), 26.11(C11), 18.06 (C12), 163.16 (C2'), 108.84 (C3'), 164.52 
(C4'), 124.00 (C5'), 115.09 (C6'), 158.15 (C7'), 114.46 (C8'), 153.33 (C9'), 118.18 (C10'), 6.56 (C11'), 
99.91 (C1''), 71.07 (C2''), 73.20 (C3''), 82.85 (C4''), 79.83 (C5''), 29.08 (C6''), 23.34 (C7''), 61.87 (C8''), 
167.30 (C9''), 99.84 (C1'''), 70.21 (C2'''), 68.85 (C3'''), 72.34 (C4'''), 72.34 (C5'''), 62.73 (C6'''),20.58-
20.83 (4*CH3CO), 171.25-172.09 (4*CH3CO). ESI+811 [M+H]+, HRMS: 943.3360, calculated for 
C45H54N2O20: 943.3348. 
3.4 DNA Gyrase Assay 
The DNA gyrase assay was performed according to the supplier’s procedure withnovobiocin, glucosyl-
novobiocin and galactosyl-novobiocin as inhibitors.  
DNA gyrase (1U) wasincubated with relaxed pBR322 (0.5μg) in a reaction volume of 30 μL at 37C for 
1 hr in  TRIS-HCl (35mM, pH 7.5), KCl (24mM), MgCl2 (4mM), DTT (2mM), spermidine (1.8mM), ATP 
(1mM), glycerol (6.5%, w/v) and albumin (0.1mg/mL). 
After incubation the mixture was treated with equal volumes of chloroform /isoamyl alcohol (24:1) 
and the end point was determined by separating relaxed and super twisted plasmid pBR322 DNA by 
agarose gel electrophoresis (0.8% agarose with TBE buffer), running without ethidium bromide. After 
electrophoresisthe gel was soaked in tank buffer containing ethidium bromide for one and half hours. 
3.5 Docking studies and visualization 
The crystal structure of the DNA gyrase (PDB id:1AJ6) was used as a receptor in docking studies.  The 
ICM-Pro Molsoft software (Molsoft LLC, www.molsoft.com) was used to carry out the docking studies. 
Ligand No. 1 (novobiocin) was extracted from crystal structure and redocked in the same position. The 
parameters used in obtaining the redocked conformation were used to dock other ligands. ICM lig-
edit module was used to generate ligand 2 and. 3. A binding pocket was defined by using ICM Finding 
Pocket tools. The docking grid was centred on the best pocket found, taking into account all residues 
around existing ligand (novobiocin). For each compound we used the APF superposition template 
method to obtain the most reliable results. The hydrogen bond analysis of obtained complexes was 
carried out with ICM Molsoft software. 
3.6 Activity of novobiocin and novobiocin derivatives against Escherichia coli 
The MICs of novobiocin and novobiocin derivatives were determined by micro-broth dilution 
technique in cation-adjusted Mueller-Hinton broth and with a bacterial inoculum of 5x105 CFU/ml. 
Microtitre plates were incubated aerobically at 37ºC and read after 24h. The concentration range 
tested was 128 to 0.12g/ml. 
4. Conclusions 
In conclusion, Koenigs-Knorr glycosylation gave only a thermodynamic controlled 4'-OH product. DMF 
proved to be the best condition, while other conventional catalysts were detrimental to the yield. 
Phase transfer reaction gave a kinetic controlled 5-OH product but still produced thermodynamic 
controlled 4'-OH, di-glycosylated glycosylation products and, possibly the more difficult 3''-OH 
glycosylation in the presence of a stronger base. This provides a powerful tool to generate various 
products. It also demonstrated that the galactose modification increased the antimicrobial activity 
probably due to the enhanced uptake ability.  
 
Highlights 
 Reaction conditions control glycosylation position. 
 Glycosyl-novobiocin weaken the binding to DNA gyrase.  
 Sugar moiety created new additional binding to the protein target. 
 Galactosylation may enhance the activity against certain E. coli isolates. 
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